Cholic acid (CA) and indoxyl sulfate (IS) are toxins associated with biliary and renal disease. Protein binding prevents removal by traditional dialysis. Dissolving binding molecules such as albumin in dialysate enables detoxification. We created a benchtop albumin dialysis test platform. We used it to validate a mathematical model of CA/IS removal. Toxin-containing blood analog solution was dialyzed using two dialyzers at five flow rates against albumin dialysate. One condition was used to estimate toxin binding affinity to albumin and the free toxin transmembrane transfer coefficient (KfreeA). Other conditions validated modeling results and revealed the impact of dialysate flow rate and dialyzer properties on detoxification (measured by mass spectrometry). We accurately predicted CA/IS removal. The normalized root mean squared error never exceeds 11.5% of the starting amount. Increasing dialysate side flow rate up to 150 mL/min improved toxin removal. Further increases produced no benefit. KfreeA was independent of flow rate. Our data fits a result from the newly developed AMOR system, in which total bile acids declined with treatment. This model and benchtop setup aim to predict clinical CA/IS clearance and optimize device design for clinical trials. This will mean fewer unsuccessful trials and enable testing of new dialysate formulations.
CuvelierCTintillierMMigaliG, et al. Albumin losses during hemodiafiltration: all dialyzers are not created equal - a case report. BMC Nephrol2019; 20: 392.
MałkowskiP.Human albumin: old, new, and emerging applications. Ann Transplant2013; 18: 205–217.
4.
NovokhodkoADuNHaoS, et al. Predicting the impact of polysulfone dialyzers and binder dialysate flow rate on bilirubin removal. Bioengineering2024; 11: 1262.
5.
FuchsCDTraunerM.Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol2022; 19: 432–450.
6.
BarretoFCBarretoDVLiabeufS, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. CJASN2009; 4: 1551–1558.
7.
RohacovaJMarinMLMirandaMA.Complexes between fluorescent cholic acid derivatives and human serum albumin. A photophysical approach to investigate the binding behavior. J Phys Chem B2010; 114: 4710–4716.
8.
Sánchez-OspinaDMas-FontaoSGracia-IguacelC, et al. Displacing the burden: a review of protein-bound uremic toxin clearance strategies in chronic kidney disease. JCM2024; 13: 1428.
9.
DevineEKrieterDRüthM, et al. Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins2014; 6: 416–429.
10.
LeongSSirichT.Indoxyl sulfate—review of toxicity and therapeutic strategies. Toxins2016; 8: 358.
11.
MeyerTWPeattieJWTMillerJD, et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. JASN2007; 18: 868–874.
12.
MeyerTWWaltherJPagtalunanME, et al. The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int2005; 68: 867–877.
13.
JungAKorohodaPKrisperP, et al. Bile acid kinetic modeling in end-stage liver support patients. Biocybern Biomed Eng2020; 40: 764–773.
14.
BellmannRGraziadeiIWFeistritzerC, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl2004; 10: 107–114.
15.
StadlbauerVKrisperPBeuersU, et al. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J2007; 53: 187–193.
16.
AhmadSNovokhodkoALiouIW, et al. Development and first clinical use of an extracorporeal artificial multiorgan system in acute-on-chronic liver failure patients. ASAIO J. Epub ahead of print 29 February 2024. DOI: 10.1097/MAT.0000000000002174.
17.
NovokhodkoAHaoSAhmadS, et al. Non-cell-based extracorporeal artificial liver systems: historic perspectives, approaches and mechanisms, current applications, and challenges. Artif Organs2025; 49: 925–944.
18.
FuhrmannVWeberTRoedlK, et al. Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure. Ann Intensive Care2020; 10: 96.
19.
DaugirdasJTDepnerTAInrigJ, et al. KDOQI Clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis2015; 66: 884–930.
20.
LewisBPanveliwallaDTabaqchaliS, et al. Serum-bile-acids in the stagnant-loop syndrome. Lancet1969; 293: 219–220.
ElootSVosJ-YVosF, et al. Middle molecule removal in low-flux polysulfone dialyzers: Impact of flows and surface area on whole-body and dialyzer clearances. Hemodial Int2005; 9: 399–408.
23.
DukhinSSTabaniYLaiR, et al. Outside-in hemofiltration for prolonged operation without clogging. J Membr Sci2014; 464: 173–178.
24.
BieberSHalldorsonJBFinnE, et al. Extracorporeal delivery of rAAV with metabolic exchange and oxygenation. Sci Rep2013; 3: 1538.
25.
SangeethaMSKandaswamyALakshmi DeepikaC, et al. Finite element analysis for comparing the performance of straight and undulated fibers in altering the filtering efficiency of hemodialyzer membranes. J Mech Med Biol2019; 19: 1850063.
26.
DepnerTAGreeneTDaugirdasJT, et al. Dialyzer performance in the HEMO study: in Vivo K 0 A and true blood flow determined from a model of cross-dialyzer urea extraction. ASAIO J2004; 50: 85–93.
27.
PeiYSunYSunS, et al. Albumin dialysis in artificial liver support systems: open-loop or closed-loop dialysis mode?ASAIO J2015; 61: 324–331.
28.
ShcherbakovMBrebelsAShcherbakovaN, et al. A survey of forecast error measures. World Appl Sci J2013; 24: 171–176.
29.
RunbangT.Uremic Toxins Removal in Kidney Dialysis through Molecularly Imprinted Polymers and Membranes. PhD thesis, Seattle, WA: University of Washington, 2022. https://hdl.handle.net/1773/48792
30.
HanLWWangLShiY, et al. Impact of microbiome on hepatic metabolizing enzymes and transporters in mice during pregnancy. Drug Metab Dispos2020; 48: 708–722.
31.
XieGWangYWangX, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC–MS/MS. J Proteome Res2015; 14: 850–859.
32.
DingWZouLSunS, et al. A new method to increase the adsorption of protein-bound toxins in artificial liver support systems: preconcentration method in liver support. Artif Organs2014; 38: 954–962.
33.
DonatiGLa MannaGCiancioloG, et al. Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up. Artif Organs2014; 38: 125–134.
34.
StefoniSColìLBolondiL, et al. Molecular Adsorbent Recirculating System (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int J Artif Organs2006; 29: 207–218.
35.
StauberREKrisperPZollnerG, et al. Extracorporeal albumin dialysis in a patient with primary sclerosing cholangitis: effect on pruritus and bile acid profile. Int J Artif Organs2004; 27: 342–344.
36.
SturmEFranssenCGouwA, et al. Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver2002; 22: 72–75.
37.
HassaneinTIToftengFBrownRS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology2007; 46: 1853–1862.
38.
HartmannJHarmS.Removal of bile acids by extracorporeal therapies: an in vitro study. Int J Artif Organs2018; 41: 52–57.
39.
ZhangMMiaoYZhangP, et al. Clearance of protein-bound uremic toxins using anion nanotraps with record high uptake. ACS Appl Mater Interfaces2024; 16: 68426–68436.
40.
BrettschneiderFTölleMvon der GietM, et al. Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique: thoughts and progress. Artif Organs2013; 37: 409–416.
41.
SuP-YLeeY-HKuoL-N, et al. Efficacy of AST-120 for patients with chronic kidney disease: a network meta-analysis of randomized controlled trials. Front Pharmacol2021; 12: 676345.
42.
CamilleriMGoresGJ.Therapeutic targeting of bile acids. Am J Physiol Gastroint Liver Physiol2015; 309: G209–G215.
43.
DeltombeODe LoorHGlorieuxG, et al. Exploring binding characteristics and the related competition of different protein-bound uremic toxins. Biochimie2017; 139: 20–26.
44.
GullNSenPKabir-ud-Din, et al. Effect of physiological concentration of urea on the conformation of human serum albumin. J Biochem2006; 141: 261–268.
45.
CharraB.Is Kt/V urea a satisfactory measure for dosing the newer dialysis regimens?Semin Dial2001; 14: 8–9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
